HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...

Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...

The Standard Shopping Shortlist: What to shop, see and know in February 2026 - The hot-off-the-press launches and shiny ...

From contrast therapy to rhythmic health, experts are placing renewed focus on recovery, rest, and repair. Read on for some ...

As of Wednesday, January 28, Yatsen Holding Limited’s YSG share price has surged by 9.05%, which has investors questioning if this is right time to sell.

From contrast therapy to rhythmic health, experts are predicting a renewed focus on recovery, rest, and repair The wellness ...

UC alumni and faculty from seven campuses are leading the way for the next generation across AI, entrepreneurship, health care, social impact and more.